RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast

Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 31, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at . A webcast replay will be available in the investor relations section on the company’s website following the completion of the call.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

Media Contact:



EN
25/03/2025

Underlying

RANIRANI THERAPEUTICS HLDGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ...

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule - - Preclinical data of four incretin-based molecules underscores the RaniPill® platform's potential to facilitate the oral delivery of a diverse array of obesity treatments - - Phase 1 st...

March 31, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivale...

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 – - Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in ...

March 26, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financia...

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2024 and provide a business update on Monday, March 31, 2025 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p....

March 25, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Announces Preclinical Data Demonstrating Successful ...

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC - Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated with no serious adverse events - - Data adds to growing body of evidence of the RaniPill® platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate i...

February 5, 2025 1 EN
 PRESS RELEASE
Free
RANI RANI THERAPEUTI...

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provid...

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA...

November 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch